Get our free guide to translational models that deliver reliable data and de-risk decisions early.
New research model pricing is now available!
Secure your source for quality antibody production. Learn how our experience and flexibility can meet your needs for both small scale and large scale production.
Learn how our whole slide imaging and precision AI-driven quantitative image analysis can support your drug discovery and development projects.
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
November 15-19, 2025 San Diego, CA Booth #2135 Each year, scientists from around the world congregate to discover new ideas, share their research, and experience the best the field...
November 16-19, 2025 Phoenix, AZ Booth #507 ACT is a global community of professional scientists representing the pharmaceutical and biotech industries, regulatory agencies, contra...
March 22-25, 2026 San Diego, CA Booth #1711 Toxicologists and scientists will attend the annual ToxExpo to communicate industry-leading ideas and best practices. With live, semi-li...
November 25, 2025 Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021...
November 21, 2025 WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading c...
November 17, 2025 Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $51...
Undertaking a large-scale rederivation project can be complex and resource-intensive, with hundreds of animal lines at stake. Choosing the right commercial partner is the most critical step to ensure both scientific integrity and operational success.
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2025 Inotiv. All Rights Reserved.